1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
IBCL - 334
Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis
Part of Topic
Indolent B-Cell Lymphoma (IBCL)
Context:
Data on the healthcare professionals (HCPs) involved in administering subcutaneous (SC) bispecific antibodies (BsAbs) and the associated time commitments for HCPs and patients are limited.
Objective:
To estimate the practice efficiency of fixed duration mosunetuzumab (Mosun) SC and treat-to-progression epcoritamab (Epcor) SC in third line or later (3L+) follicular lymphoma (FL).
Methods:
Practice efficiency of Mosun SC and Epcor SC was compared over 1 year. Data on premedication requirements, BsAb dosing schedules and mean duration of treatment (DOT) were based on respective pivotal Phase I/II trials (NCT02500407; NCT03625037) and United States (US) prescribing labels. Premedications before BsAb administration were assumed to be administered by HCPs only. Corticosteroids on subsequent days for Epcor were assumed to be dispensed through one-time retail pharmacy visits by patients. Information on HCPs involved and mean time spent by HCPs and patients was based on input by US-based clinicians. Costs were estimated using mean hourly wages from the US Bureau of Labor Statistics, adjusted to 2026 US dollars.
Results:
HCPs involved in drug preparation/verification included: pharmacy technicians, pharmacists and registered nurses. HCPs involved in patient visits included: front desk staff, laboratory technicians, pharmacy technicians, pharmacists, registered nurses, medical assistants, physician assistants and nurse practitioners. Over a year, patients receiving Mosun SC required fewer premedications (≥3 times before weekly Mosun in Cycle 1) versus Epcor SC (≥16 times, before and after weekly Epcor in Cycle 1) and fewer doses (10 doses for patients achieving complete response by Cycle 8 or at most 19 doses) versus Epcor SC (28 doses). At the respective mean DOTs, fewer BsAb administrations were required with Mosun SC (nine doses for 7.9 cycles) versus Epcor SC (28 doses for 12.2 cycles). Overall, 42 and 31 hours of HCP and patient time were saved with Mosun SC versus Epcor SC, resulting in $1,972 and $1,160 saved, respectively.
Conclusions:
In 3L+ FL, fixed duration Mosun SC demonstrated better practice efficiency, requiring less HCP and patient time, with fewer premedications and doses versus treat-to-progression Epcor SC.